⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5936644 | 0.73 | KMT2A (0.33) | — | |
| SCHEMBL791682 | 0.72 | NQO1 (0.50) | — | |
| SCHEMBL790619 | 0.69 | RAB9A (0.50) | — | |
| SCHEMBL920282 | 0.69 | LTA4H (0.48) | — | |
| SCHEMBL6446353 | 0.69 | — | — | |
| SCHEMBL146662 | 0.69 | — | — | |
| SCHEMBL4729082 | 0.68 | — | — | |
| SCHEMBL55096 | 0.67 | DAO (0.38) | — | |
| SCHEMBL170531 | 0.64 | — | — | |
| SCHEMBL2213877 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213353-A | Aryl-oxazole-oxazoline compound and preparation method and application thereof | 贵州大学 | 2022-03-22 | — | — | CN | claimed |
| EP-3402791-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2018-11-21 | — | — | EP | claimed |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | claimed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | claimed |
| WO-2017123542-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-20 | — | — | WO | claimed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | claimed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | claimed |
| US-7956051-B2 | Therapeutic amides and related compounds | ALLERGAN, INC. (US) | 2011-06-07 | — | — | US | claimed |
| EP-2247583-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2010-11-10 | — | — | EP | claimed |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-06-03 | — | — | US | claimed |
| JP-2009535421-A | — | — | 2009-10-01 | — | — | JP | claimed |
| WO-2009094286-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2009-07-30 | — | — | WO | claimed |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2009-07-30 | — | — | US | claimed |
| US-7491844-B2 | Therapeutic cyclopentane derivatives | ALLERGAN, INC. (US) | 2009-02-17 | — | — | US | claimed |
| EP-2021322-A2 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | Allergan, Inc. (US) | 2009-02-11 | — | — | EP | claimed |
| WO-2007130902-A2 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. | 2007-11-08 | — | — | US | claimed |
| CN-114213353-B | Aryl-oxazole-oxazoline compound and preparation method and application thereof | 贵州大学 | 2023-04-14 | — | — | CN | disclosed |
| US-5116986-A | HETEROAROMATIC AMINE DERIVATIVES | DR. KARL THOMAE GMBH (DE) | 1992-05-26 | — | — | US | disclosed |